Barbara E Bierer

Barbara Emily Bierer, MD

Professor of Medicine (Pediatrics), HMS
Member, HMS Center for Bioethics

Barbara Bierer, MD is a Professor of Medicine (Pediatrics) at Harvard Medical School (HMS), and a hematologist/oncologist at the Brigham and Women's Hospital (BWH). She received her MD from HMS. She is the director of the Regulatory Foundations, Law and Ethics Program of the Harvard Catalyst, the Harvard Clinical and Translational Science Award, and the director of regulatory policy, SMART IRB. Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve the ethics, conduct, and regulatory environment for multi-site, multi-national clinical trials. She is a co-founder of COVID-19 Collaboration Platform, a platform for cooperation in research. In 2017, the MRCT Center launched the non-profit Vivli, a global clinical research data sharing platform. From 2003-2014, she served as Senior Vice President, Research, at BWH and was the institutional official for human subjects and animal research, for biosafety and for research integrity at the BWH. She initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. Dr. Bierer established and directed the Center for Faculty Development and Diversity at the BWH; for these efforts, she was the first recipient of the HMS Harold Amos Faculty Diversity Award.

Publications View
CD4, CD8 and CD2 in T cell adhesion and signaling.
Authors: Authors: Collins TL, Hahn WC, Bierer BE, Burakoff SJ.
Curr Top Microbiol Immunol
View full abstract on Pubmed
Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas.
Authors: Authors: Fruman DA, Mather PE, Burakoff SJ, Bierer BE.
Eur J Immunol
View full abstract on Pubmed
Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12.
Authors: Authors: Kaye RE, Fruman DA, Bierer BE, Albers MW, Zydowsky LD, Ho SI, Jin YJ, Castells MC, Schreiber SL, Walsh CT, et al.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype.
Authors: Authors: Arceci RJ, Stieglitz K, Bierer BE.
Blood
View full abstract on Pubmed
Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin.
Authors: Authors: Calvo V, Crews CM, Vik TA, Bierer BE.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase.
Authors: Authors: Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE.
Science
View full abstract on Pubmed
A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen.
Authors: Authors: Hahn WC, Rosenstein Y, Calvo V, Burakoff SJ, Bierer BE.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59.
Authors: Authors: Hahn WC, Menu E, Bothwell AL, Sims PJ, Bierer BE.
Science
View full abstract on Pubmed
Molecular cloning of a 25-kDa high affinity rapamycin binding protein, FKBP25.
Authors: Authors: Jin YJ, Burakoff SJ, Bierer BE.
J Biol Chem
View full abstract on Pubmed
Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells.
Authors: Authors: Höllsberg P, Wucherpfennig KW, Ausubel LJ, Calvo V, Bierer BE, Hafler DA.
J Immunol
View full abstract on Pubmed